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Kaempferol, a natural dietary flavonoid, is well known to possess chemopreventive and therapeutic anticancer
efficacy; however, its antimetastatic effects have not been mechanistically studied so far in any cancer model.
This study was aimed to investigate the inhibitory effect and accompanying mechanisms of kaempferol on
epithelial-to-mesenchymal transition (EMT) and cell migration induced by transforming growth factor-β1 (TGF-β1).
In human A549 non–small lung cancer cells, kaempferol strongly blocked the enhancement of cell migration by
TGF-β1–induced EMT through recovering the loss of E-cadherin and suppressing the induction of mesenchymal
markers as well as the upregulation of TGF-β1–mediated matrix metalloproteinase-2 activity. Interestingly,
kaempferol reversed TGF-β1–mediated Snail induction and E-cadherin repression by weakening Smad3 binding to
the Snail promoter without affecting its C-terminus phosphorylation, complex formation with Smad4, and nuclear
translocation under TGF-β1 stimulation. Mechanism study revealed that the phosphorylation of Smad3 linker
region induced by TGF-β1 was required for the induction of EMT and cell migration, and selective downregulation
of the phosphorylation of Smad3 at Thr179 residue (not Ser204, Ser208, and Ser213) in the linker region was
responsible for the inhibition by kaempferol of TGF-β1–induced EMT and cell migration. Furthermore, Akt1 was
required for TGF-β1–mediated induction of EMT and cell migration and directly phosphorylated Smad3 at Thr179,
and kaempferol completely abolished TGF-β1–induced Akt1 phosphorylation. In summary, kaempferol blocks TGF-
β1–induced EMT and migration of lung cancer cells by inhibiting Akt1-mediated phosphorylation of Smad3 at
Thr179 residue, providing the first evidence of a molecular mechanism for the anticancer effect of kaempferol.
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Non–small-cell lung cancer (NSCLC) is the most common type of
lung cancer. NSCLC shows a poor prognosis and accounts for theleading cause of cancer-related death every year worldwide [1].
Because of the lack of robust and dependable molecular markers for
the early diagnosis, most patients with NSCLC present locallyControl (1020420), Ministry for Health and Welfare, Republic of Korea.
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Moreover, the metastasis of lung cancer cells is a major contributor in
aggressiveness of NSCLC and is responsible for the main cause of
deaths in lung cancer patients. Therefore, identifying of the key
factors that contribute to the lung metastatic process and a better
understanding of the molecular mechanisms underlying lung cancer
metastasis are crucial in providing a promising approach for lung
cancer therapy that target metastasis.
Tumor metastasis is a dynamic multistep cascade process. In the
metastatic process, epithelial-to-mesenchymal transition (EMT) is an
important morphogenetic event for triggering metastasis from
primary tumors and is characterized by the loss of E-cadherin–
mediated cell-cell junction and the upregulation of mesenchymal
markers including N-cadherin, vimentin, and fibronectin [2,3].
Therefore, changes during EMT lead to the transition of a polarized
epithelial phenotype to a migratory mesenchymal phenotype, and
then cells degrade extracellular matrix by activating matrix metallo-
proteinases (MMPs) and have invasive characteristics.
Transforming growth factor-β1 (TGF-β1), a prototypical member
of the TGF-β superfamily, is a multifunctional cytokine that regulates
cell proliferation, differentiation, apoptosis, and migration [4]. In
normal physiologic condition, TGF-β1 has tumor-suppressive
functions through inhibiting cell proliferation and promoting
apoptosis. However, TGF-β1 acts also as a metastatic inducer by
promoting EMT in late-stage tumor progression [5]. Molecular
signaling mechanism studies on TGF-β1–induced EMT indicate
crucial roles of Smad3 signaling pathway. Depletion of Smad3
completely abolishes TGF-β1 induction of EMT [6–8]. Smad3 acts
as a transcriptional activator of E-cadherin repressors such as Snail,
Slug, and Twist [9–11]. Smad3 also negatively regulates E-cadherin
by upregulating ZEB1 and ZEB2 via microRNA-200 pathway [12].
Smad3 is a key mediator of TGF-β signaling pathway. Upon
TGF-β1 stimulation, TβRI is activated by TβRII and mediates the
phosphorylation of the conserved COOH-tail serine residues of
Smad3. The phosphorylated Smad3 interacts with Smad4 and
translocates from the cytosol into the nucleus, where it regulates
transcription of target genes [13,14]. However, the regulatory
mechanisms by which Smad3 determines the functional outcome
of TGF-β1 responses under physiologic and pathologic conditions
have yet to be fully elucidated. Smad3 linker region is a less conserved
intermediate region that connects between conserved Mad-homology
(MH) 1 and MH2 domains and contains several threonine and serine
residues (Thr179, Ser204, Ser208, and Ser213) that phosphorylated
by fundamental signaling kinases in a strongly cell context-dependent
manner [15–19]. Several lines of recent evidence indicate the
phosphorylation of the linker region of Smad3 as a crucial
determinant of distinct cellular responses to TGF-β1 in normal and
cancer cells. For example, in early carcinogenic process, hepatitis B
virus X protein shifts hepatocytic TGF-β signaling from the
tumor-suppressive Smad3 pathway to the oncogenic Smad3 pathway
through inducing c-Jun NH2-terminal kinase–mediated phosphory-
lation of Smad3 linker region [20]. Constitutively activated Ras
confers a selective advantage on benign tumors by inducing the
phosphorylation of Smad3 linker region, leading to carcinoma in situ
[21]. Hydrogen peroxide–mediated phosphorylation of Smad3 linker
region opposes the antiproliferative responses of epithelial cells
induced by TGF-β1 [22]. Therefore, the pharmacologic inhibition of
Smad3 phosphorylation in the linker region may prevent progression
to advanced carcinoma by suppressing oncogenic TGF-β signaling.Kaempferol (3,5,7-trihydroxy-2-(-4-hydroxyphenyl)-4H-1-
benzopyran-4-one) is a common natural flavonoid (chemical
structure as shown in Figure 1A) that is abundant in tea, grapes,
berries, and cruciferous vegetables [23]. In several types of human
cancer cells, kaempferol acts as a potent antitumor growth agent that
inhibits phosphatidylinositol-3-kinase (PI3K) and ribosomal S6
kinase activities [24–26] and increases the expression of tumor
suppressor, phosphatase and tensin homolog [27]. Kaempferol also
inhibits tumor angiogenesis and expression of MMP-2 [28,29].
However, the effect of kaempferol on the cancer metastasis of
NSCLC, as well as the underlying mechanisms of the effect, has not
yet been reported. In the present study, we investigated the molecular
mechanisms by which kaempferol elicits its anticancer activity against
metastatic potentials induced by TGF-β1 in human NSCLC cell
lines. Our data clearly demonstrate that kaempferol inhibits
TGF-β1–induced EMT, migration, and invasiveness of A549 lung
cancer cells by suppressing Akt1-mediated phosphorylation of Smad3
at Thr179 residue in the linker region.
Experimental Procedures
Materials
Recombinant TGF-β1 was purchased from R&D systems
(Minneapolis, MA). Kaempferol was obtained from Sigma-Aldrich
(St. Louis, MO). AktIV, LY294002, U0126, and SB431542 were
purchased from Calbiochem (San Diego, CA). Small interfering
RNAs for control, Smad2, and Smad3 were obtained from Santa
Cruz Biotechnology (Santa Cruz, CA).
Cell Culture
A549, human non–small lung cancer cell line, was obtained from
American Type Culture Collection (Manassas, VA). The cells were
cultured in monolayers at 37°C in a 5% CO2 incubator in
RPMI1640 medium supplemented with 2 mM L-glutamine, 10%
heat-inactivated fetal bovine serum, 100 U/ml penicillin, and
100 mg/ml streptomycin.
Lentiviral Vector Production and Infection
The lentiviral vectors carrying human Smad3 wild type, Smad3
(EPSM), and Smad3 (T179V) were cloned from pCMV-Myc-Smad3
wild type, pCMV-Myc-Smad3 (EPSM), and pCMV-Myc-Smad3
(T179V) (a gift from Dr. Fang Liu; The State University of New
Jersey). The lentiviral vector pCAG was digested with Mlu5 and
Nhe3, and the two primers used are as follows: forward,
5’-GATCACGCGTGGATCCCATCGATTTAAAGCT-3’; reverse,
5’-GATCGCTAGCCCCTCTAGATGCATG-3’. For the produc-
tion of lentivirus, 293T cells were co-transfected with pCAG vector
together with psPAX2 and pMD2. G (Addgene, Cambridge, MA) by
FuGENE6. The viral supernatant was collected 72 hours after
transfection, cleared by centrifugation (2000 rpm/min, 10 minutes,
and 4°C), and then filtered through a 0.45-μm filter (Millipore,
Billerica, MA). Target cells (1 × 105/well) were seeded in six-well
plate, and after incubation at 37°C for 24 hours, the medium of each
well was replaced with 1-ml viral suspension supplemented with 8
mg/ml Polybrene (Sigma-Aldrich). Then, the plates were centrifuged
at 1200 rpm for 30 minutes at room temperature, followed by
12-hour incubation in standard cell culture condition, and media
were replaced with fresh Dulbecco’s modified Eagle’s medium. After
48 hours of additional incubation, the protein levels of each gene were
analyzed by immunoblotting.
Figure 1. Kaempferol (KF) inhibits TGF-β1–induced EMT in A549 lung cancer cells. (A) Chemical structure of KF. (B) Phase contrast images
of cells treated with DMSO, 5 ng/ml of TGF-β1, or 5 ng/ml of TGF-β1 plus 25 μM of KF for 24 hours. (C) A549 cells were pretreated with
25 μM of KF at the indicated concentrations for 30 minutes and then stimulated with 5 ng/ml of TGF-β1 for 48 hours. Then, the cells were
subjected toWestern blot analysis for E-cadherin, N-cadherin, and smooth muscle α-actin (SMα actin). β-Actin levels were monitored as a
loading control for whole-cell extracts. (D) A549 cells were pretreated with DMSO or 25 μMof KF for 30 minutes before 5 ng/ml of TGF-β1
treatment for 48 hours and then subjected to immunofluorescence staining for E-cadherin (green), N-cadherin (red), and vimentin (red).
DAPI (blue) was used to stain nuclei.
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The pSG5-p110α (K227E), which encodes a constitutively active
p110α (CA-p110α), the catalytic subunit of PI3K, and
pSG5-p85ΔiSH2-N (deleted for amino acids 478-513 and widely
referred to as pSG5-Δp85), which encodes a dominant-negative
mutant of p85 (DN-p85), a regulator of PI3K, were gifts from Dr. J.
Downward (Cancer Research, UK). The pCMV2-Akt1 (E40K),
which encodes a constitutively active Akt1 (CA-Akt1), was provided
by Dr. Naoya Fujita (University of Tokyo, Japan). The pcDNA3-
HA-Akt1 (K179M), which encodes a dominant-negative mutant of
Akt1 (DN-Akt1), was a gift from Dr. Kwon Young-Guen (Yeonse
University, Korea). A549 cells in six-well plates (5 × 105 cells per
plate) were co-transfected with 0.5 μg of a luciferase reporter plasmid
containing the human E-cadherin promoter (gift from Dr. Kyung Lib
Jang, Pusan National University, Korea), the human Snail promoter
(gift from Dr. Guhung Jung, Seoul National University), or an
artificial SBE4-Luc reporter plasmid containing four tandem repeats
of Smad-binding elements together with 0.2 μg of the β-galactosidase
expression plasmid pCMV-LacZ with the use of FuGENE 6 reagent
(Roche, Mannheim) according to the manufacturer’s instructions.
Luciferase reporter activity was assessed on a luminometer with a
dual-luciferase Reporter Assay System (Promega, Madison, WI). The
activity of β-galactosidase was also measured and was used tonormalize luciferase activity. The results represent the average and SD
of three independent experiments.
Gelatin Zymography
The activity of MMP2 in culture medium was assessed by gelatin
zymography. After serum starvation for 24 hours, A549 cells were
subjected to treatment and then incubated further for 24 hours. The
supernatants were collected, centrifuged at 3000×g for 10 minutes,
concentrated using Amicon Ultra Centrifugal Filter Units (Millipore),
and quantified using Bio-Rad protein assay reagent. Proteins (30 μg)
were subjected to SDS-PAGEon a 7.5% gel containing gelatin (2mg/ml).
For detection of gelatinolytic activity, the gel was incubated for overnight at
37°C in a solution containing 50 mMTris-HCl, pH 7.5, 10 mMCaCl2,
150 mM NaCl, and 0.02% sodium azide; stained with solution
containing 0.1% Comassie Brilliant Blue, 25% methanol, and 0.7%
acetic acid for 30minutes; and destainedwith a solution of 30%methanol
and 10% acetic acid.
Scratch Wound Migration Assay
Confluent monolayers of A549 cells were scratched using a sterile
200-μl pipette tip to generate a cell-free gap between two adjoining
areas. After removal of the loose cells by twice washes with PBS, cells
were subjected to treatment. Scratched wound healing was monitored
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24 hours of treatment. The area of migrating cells was randomly
photographed at three separate sites along the length of the scratch.
Transwell Migration Assay
A549 cells uninfected or infected with lentivirus were serum
starved (0.1% FBS) overnight and then trypsinized and resuspended
in RPMI1640 (serum free) medium at 2 × 105 cells/ml. A total of 250
μl of suspension was applied to the upper chamber of Transwell insert
(8-μm pore size, Corning). Cells were immediately exposed to
treatment and allowed to migrate for 24 hours toward chemoattract-
ing complete medium present in the bottom chamber. Unmigrated
cells on the upper surface were removed, and migrated cells at the
bottom of the insert were fixed in methanol and stained with eosin
and hematoxylin for cell counting. The number of migrated cells was
counted in five randomly selected fields per filter. The results
represent the average and SD of three independent experiments.
Western Blotting and Immunoprecipitation
Cellular contents were extracted in lysis buffer [50 mM Tris-HCl
(pH 7.4), 150 mM NaCl, 0.5% Nonidet P-40, 0.5% sodium
deoxycholate, 5 mM EDTA, 2 mM DTT, 1 mM sodium
orthovanadate, 10 mM β-glycerphosphate, 1 mM sodium fluoride,
1 μM microcystin, 1 mM phenylmethylsulfonyl fluoride, 5 μg/ml
leupeptin, 10 μg/ml aprotinin] at 4°C. Cell lysates were clarified by
microcentrifugation at 12,000 rpm/min at 4°C for 10 minutes. The
supernatants were recovered, and total protein concentrations
were measured using Bio-Rad protein assay reagent. Proteins in the
cell lysates (500 μg) were immunoprecipitated with 2 μg of a
monoclonal anti-Smad3 antibody, followed by incubation with
protein A/G-Sepharose beads. The immunoprecipitates were washed
with lysis buffer four times. Immunoprecipitates or equivalent
amounts of total cellular proteins were heated at 95°C for 3 minutes
and then separated by SDS-PAGE, followed by electrotransfer to
polyvinylidene difluoride membranes. The membranes were subse-
quently blocked for 1 hour with Tris-buffered saline containing
0.05% (v/v) Tween 20 and 5% (w/v) nonfat dry milk and then
incubated with appropriate antibodies [anti-myc and anti-vimentin
(Santa Cruz Biotechnology), anti-Smad2 and anti-Smad3 (Zymed),
anti-phospho-Smad3 (Ser423/425) and anti-phospho-Akt (Ser426)
(Cell Signaling Technology, Danvers, MA), and anti-E-cadherin and
anti–N-cadherin (BD Transduction laboratories, Lexington, KY),
anti–smooth muscle α-actin and anti–β-actin (Sigma-Aldrich)].
Primary antibody binding was detected using horseradish peroxi-
dase–conjugated goat anti-mouse or anti-rabbit immunoglobulin G
secondary antibody (Santa Cruz Biotechnology) visualized with
Supersignal West Pico Chemiluminscent Substrate (Pierce/Thermo-
Scientific, Rockford, IL).
Chromatin Immunoprecipitation (ChIP) Assay
Cells were cross-linked with 1% formaldehyde at room temper-
ature for 15 minutes, rinsed with ice-cold PBS, and collected. After
centrifugation, the precipitate was washed sequentially with 1 ml of
buffer I (0.25% Triton X-100, 10 mM EDTA, 0.5 mM EGTA,
10 mM HEPES, pH 6.5) and buffer II (200 mM NaCl, 1 mM
EDTA, 0.5 mM EGTA, 10 mM HEPES, pH 6.5). Cells were then
resuspended in 0.3 ml of lysis buffer [1% SDS, 10 mM EDTA,
50 mM Tris-HCl, pH 8.1, 1× protease inhibitor cocktail (Roche
Molecular Biochemicals, Indianapolis, IN)] and sonicated 10 timesfor 10 seconds, followed by centrifugation for 10 minutes at 13,000
rpm. The sheared chromatin was incubated on a rolling shaker
overnight at 4°C with antibody (2 μg per reaction) and protein
A-Sepharose beads [45 μl of a 50% slurry in 10 mM Tris-HCl
(pH 8.1) and 1 mM EDTA]. The following rabbit or mouse
polyclonal antibodies were used: c-Myc (9E10) and control IgG from
Santa Cruz Biotechnology and Smad3 from Invitrogen (Carlsbad,
CA). The antibody-bound protein/DNA complexes were precipitated
and washed sequentially for 10 minutes each in TSE I [0.1% SDS,
1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl (pH 8.1),
150 mM NaCl], TSE II [0.1% SDS, 1% Triton X-100, 2 mM
EDTA, 20 mM Tris-HCl (pH 8.1), 500 mM NaCl], and buffer III
[0.25 M LiCl, 1% NP-40, 1% deoxycholate, 1 mM EDTA, 10 mM
Tris-HCl (pH 8.1)]. The captured genomic DNA was eluted,
cross-linking was reversed at 94°C for 15 minutes, and proteins were
removed by treatment with Proteinase K at 37°C for 1 hour. Ten
percent of total genomic DNA from the nuclear extract was used as
input. The primer used for detection of Snail promoter sequence as
follows: forward primer, 5’-CGCTCCGTAAACACTGGATAA-3’;
reverse primer, 5’-GAAGCGAGGAAAGGGACAC-3’. The samples
were amplified by conventional polymerase chain reaction (PCR)
using the above Smad3 Snail promoter-specific forward and reverse
primers and Platinium Taq DNA polymerase (Invitrogen).
Semiquantitative Reverse Transcriptase (RT)-PCR
Total cellular RNA was extracted from cells using the phenol-
guanidinium isothiocyanate method [30]. Two micrograms of RNA was
reverse transcribed for 1 hour at 42°C and amplified by PCR using specific
primers for human Snail (sense, 5’-GGGCAGGTATGGAGAGGAAGA-3’;
antisense, 5’-TTCTTCTGCGCTACTGCTGCG-3’) and β-actin (sense,
5’-ACGTTGCTATCCAGGCTGTG-3’; antisense, 5’-GCGACGTAG
CACAGCTTCTC-3’; internal control). The detailed PCR condition for
Snail involved 30 cycles of denaturation at 94°C for 30 seconds, annealing
at 55°C for 30 seconds, and elongation at 72°C for 60 seconds. Amplified
PCR products were subjected to electrophoresis on 1% agarose gel and
were visualized by ethidium bromide staining and photographed with
Polaroid 667 film (Cambridge, MA).
Indirect Immunofluorescence Microscopy
Cells were grown on coverslips, rinsed in PBS, fixed with 3.7%
formaldehyde in PBS for 10 minutes at 4°C, and permeabilized with
PBS supplemented with 0.5% Triton X-100 for 10 minutes at room
temperature. Permeabilized cells were rinsed three times in PBS
supplementedwith 0.5%Tween 20 and blockedwith blocking solution
(0.1% BSA in PBS, pH 7.4) for 90 minutes. Cells were rinsed three
times in PBS and incubatedwith primary antibodies against E-cadherin,
N-cadherin, vimentin, or Smad3 in humidified chamber overnight at
4°C. After rinsing three times in PBS supplemented with 0.5% Tween
20, cover slips were incubated with the secondary antibodies
Alexa-488–conjugated goat anti-rabbit or anti-mouse IgGs (Invitrogen
Molecular Probes, Eugene, OR) for 1 hour at 37°C. Cell nuclei were
counterstained with 4’, 6’-diamidino-2-phenylindole (DAPI). The
intracellular distribution of the protein was analyzed using confocal
fluorescence microscopy (Fluoview, FV-300; Olympus, Melville, NY)
with excitation at 488 nm (for Alexa-488) and 340 nm (for DAPI).
Statistical Analysis
The data are representative of three independent experiments.
Results are presented as the means ±SD. Analyses were performed
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P values less than .05 were considered significant.
Results
Inhibition of TGF-β1–induced EMT, Cell Migration, and
MMP2 Activation by Kaempferol
Because TGF-β1 has been reported to induce metastatic responses,
including EMT, motility, and invasiveness, in A549 lung cancer cells
[31], we used it as an experimental system to evaluate the
antimetastatic potential of kaempferol in cancer cells. As previously
reported, treatment with TGF-β1 dramatically induced a loss of cell
contact and acquired spindle-like shape in A549 cells, but this
morphological change was clearly blocked by pretreatment with
kaempferol (Figure 1B). In line with this result, kaempferol
completely abolished TGF-β1–mediated repression of E-cadherin
and upregulation of N-cadherin and smooth muscle α-actin in a
concentration-dependent manner (Figure 1C ). Immunofluorescence
staining of E-cadherin, N-cadherin, and vimentin in A549 cells alsoFigure 2. Kaemferol inhibits TGF-β1–induced migration and MMP2
Figure 1Dwere subjected to wound closure assay, and the wells were
cells (1 × 104) seeded on 8-mm porous Transwell chambers were
hematoxylin and eosin and counted for each of the indicated cells. Q
experiments. *P b .05, compared with vehicle-treated controls; **P
treated as in Figure 1C, the culture medium from indicated cells
zymography. (D) A549 cells were transiently transfected with MMP2
of KF at the indicated concentrations for 30 minutes and then stimulat
mean ± SD of three independent experiments. *P b .05; **P b .01, crevealed that the changes of those EMTmarker expression induced by
TGF-β1 were significantly reduced by treatment with kaempferol
(Figure 1D).
EMT is a key event in metastatic tumor progression by which
epithelial cancer develops toward more aggressive phenotype with
enhanced motile and invasive capabilities [2,3]. We thus examined
whether kaempferol affects the migration of A549 cells induced
by TGF-β1. TGF-β1–induced cell migration (Figure 2A) and
wound closure (Figure 2B) were substantially attenuated in cells
pretreated with kaempferol compared with kaempferol-untreated
cells. Upregulation of MMP2 is also known to promote the invasion
of cancer cells through the degradation of basement membrane
and extracellular matrix [32]. Gelatin zymography and reporter
gene assay revealed that TGF-β1–induced increases of secreted
MMP2 (Figure 2C ) and MMP2 gene promoter activities (Figure 2D)
were considerably abolished by treatment with kaempferol. All these
results confirm the potential of kaempferol as an inhibitor of
TGF-β1–induced EMT, cell migration, and invasiveness in A549
lung cancer cells.activation in A549 lung cancer cells. (A) A549 cells treated as in
imaged every 12 hours with Nikon90i microscope, 100×. (B) A549
treated as in Figure 1D. Transmigrating cells were stained with
uantitative data are shown as the mean ± SD of three independent
b .01, compared with TGF-β1–treated cells. (C) A549 cells were
was collected, and MMP2 activities were measured by gelatin
promoter-reporter construct. The cells were pretreated with 25 μM
ed with 5 ng/ml of TGF-β1 for 24 hours. All quantitative data are the
ompared with TGF-β1–treated cells.
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by Weakening Smad3 Binding to Snail Promoter Without
Affecting Canonical Smad3 Activation
Receptor-activated Smads, including Smad2 and Smad3, act
independently as the major intracellular mediators of TGF-β signal
transduction pathway [14]. Therefore, we analyzed the role of Smad2
and Smad3 in TGF-β1–mediated down-regulation of E-cadherin in
A549 cells. Western blot analysis revealed that depletion of Smad3
with siRNA markedly reduced the changes in E-cadherin and Snail
expression induced by TGF-β1, whereas depletion of Smad2 with
siRNA had no such effect (Figure 3A). Similar to this result,
overexpression of Smad3 (3SA), but not Smad2 (3SA), mutant
lacking phosphorylation sites in the COOH-terminal region
significantly reduced TGF-β1–induced Snail promoter activity
(Figure 3B). TGF-β1–induced Snail expression at the mRNA level
was also completely abolished by treatment with Smad3 siRNA
(Figure 3C). We next examined whether kaempferol affects the
binding of Smad3 to Snail promoter in response to TGF-β1. ChIP
was applied to measure the enrichment of Smad3 on Snail promoter
with two primers spanning its binding site. As shown in Figure 3D,
kaempferol treatment completely inhibited TGF-β1–induced re-Figure 3. Kaempferol inhibits TGF-β1–induced Smad3-mediated Sna
(A) A549 cells were transfected with control (siCon), Smad2 (siS2),
treatment for 48 hours, after which the expressions of E-cadherin, Sn
β-Actin levels were monitored as a loading control for whole ex
promoter-reporter construct (Snail-Luc) and vector for Smad2-3SA (S2
hours and then stimulated with 5 ng/ml of TGF-β1 for 24 hours. All ce
data are the mean ± SD of three independent experiments. **P b .0
(siS3) siRNAs for 24 hours before treatment with 5 ng/ml of TGF-β1 fo
were determined by RT-PCR analysis. β-Actin levels weremonitored a
DMSO, 1 μM of SB431542, or 25 μM of KF for 30 minutes before tre
ChIP assay using anti-Smad3 antibody. The purified DNA was analyz
Snail promoter. (E) A549 cells were pretreated with DMSO or 25 μM
hours. Expression of Snail mRNA was analyzed as in C. β-Actin levelcruitment of Smad3 on the −616/−623 region of Snail promoter, and
the inhibitory effect was comparable to that of SB431542, a specific
TβRI inhibitor. Consistent with this result, RT-PCR showed that
TGF-β1–induced Snail expression was significantly attenuated by
treatment with kaempferol (Figure 3E ). Furthermore, overexpression
of Smad3 (3SA) markedly attenuated TGF-β1–induced migration of
A549 cells compared with TGF-β1–treated control cells (data not
shown). These results strongly suggest that Smad3 has a functional
importance in TGF-β1–induced EMT and migration and can be a
target of kaempferol.
In the canonical TGF-β signaling pathway, activation of Smad3
by TGF-β1 is a multistep process involving its phosphorylation in
the COOH-terminal SSXS motif, complex formation with Smad4,
and translocation into the nucleus [13]. We therefore evaluated the
effect of kaempferol on TGF-β1–induced Smad3 activation in A549
cells. Interestingly, no difference on TGF-β1–induced Smad3
C-terminus phosphorylation was observed in cells pretreated with
kaempferol compared with kaempferol-untreated cells (Figure 4, A
and B). Immunoprecipitation followed by Western blotting also
showed that TGF-β1–induced endogenous Smad3/Smad4 complex
formation was not inhibited by treatment with kaempferolil induction and E-cadherin repression in A549 lung cancer cells.
or Smad3 (siS3) siRNAs for 24 hours before 5 ng/ml of TGF-β1
ail, Smad2, and Smad3 were determined by Western blot analysis.
tracts. (B) A549 cells were transiently co-transfected with Snail
3SA), Smad3-3SA (S33SA), or the corresponding empty vector for 16
lls were then assayed for relative luciferase activity. All quantitative
1. (C) A549 cells were transfected with control (siCont) or Smad3
r 3 hours, after which the expressions of Snail and Smad3 mRNAs
s a loading control for total RNA. (D) A549 cells were pretreated with
atment with 5 ng/ml of TGF-β1 for 24 hours and then subjected to
ed by RT-PCR using primers spanning the Smad3-binding sites at
of KF for 30 minutes before treatment with 5 ng/ml of TGF-β1 for 3
s were monitored as a loading control for total RNA.
Figure 4. Kaempferol does not inhibit Smad3 C-terminal phosphorylation and its complex formation with Smad4 and translocation into the
nucleus upon TGF-β1 stimulation. (A) A549 cells were pretreated with DMSO or 25 μMof KF for 30 minutes before treatment with 5 ng/ml
of TGF-β1 for the indicated periods, after which the extent of Smad3 phosphorylation at Sre423/425 was determined by Western blot
analysis. (B) A549 cells were pretreated with 25 μMof KF at the indicated concentrations for 30 minutes and then stimulated with 5 ng/ml
of TGF-β1 for 1 hour. Western blot analysis was performed as in A. β-Actin levels were monitored as a loading control for whole extracts.
(C) A549 cells were pretreated with DMSO or 25 μMof KF for 30 minutes before treatment with 5 ng/ml of TGF-β1 for 30 minutes, and cell
lysates were immunoprecipitated with anti-Smad3 antibody and immunoblotted as indicated. β-Actin levels were monitored as a loading
control for whole extracts. (D) A549 cells were treated as in A except for the TGF-β1 treatment for 10 and 90 minutes. (E) A549 cells were
treated as in B. All cells were then subjected to immunofluorescence staining for Smad3 (green). DAPI (blue) was used to stain nuclei.
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translocation of Smad3 in kaempferol-treated cells without remark-
able difference to that seen in kaempferol-untreated cells (Figure 4, D
and E ). Taken together, these results indicate that kaempferol
suppresses TGF-β1–induced E-cadherin repression by blocking
Smad3 binding to Snail promoter without affecting the canonical
process for Smad3 activation.
Kaempferol Inhibits TGF-β1–Induced EMT and Cell Migration
Through Downregulation of the Phosphorylation of Smad3 at
Thr179 in the Linker Region
There is a growing body of evidence pointing to an important role
of Smad3 linker region phosphorylation (pSmad3L) in the regulation
of Smad3 function under physiologic and pathologic condi-
tions [15,20]. To verify the requirement of pSmad3L in TGF-β1–
mediated induction of EMT and migration of A549 cells, we used
recombinant lentivirus constitutively expressing Smad3EPSM mutant,
in which all four phosphorylation sites of linker region, including
Thr179, Ser204, Ser208, and Ser213, are replaced with Val or Ala
(Figure 5A). Western blotting and immunofluorescence staining
revealed that lentivirus-mediated overexpression of Smad3EPSM
greatly reversed the changes in epithelial and mesenchymal marker
expression induced by TGF-β1 (Figure 5, B and C ). TGF-β1–
induced cell migration was also significantly attenuated in cells
infected with lentivirus carrying Smad3EPSM gene compared with
cells infected with lentivirus carrying empty vector or Smad3WT gene
(Figure 5D). In addition, TGF-β1–mediated increases of secretedMMP2 (Figure 5E ) and MMP2 gene promoter activity (Figure 5F )
were fully impaired by overexpression of Smad3EPSM but not by
overexpression of Smad3WT. These results indicate that pSmad3L is
critically required for metastatic responses induced by TGF-β1 in
A549 cells.
We next evaluated the effects of TGF-β1 and kaempferol on
pSmad3L in A549 cells. As expected, treatment with TGF-β1
strongly induced the phosphorylation of Smad3 at Thr179, Ser203,
Ser208, and Ser213 in the linker region (Figure 6, A and B).
Interestingly, we found that kaempferol specifically inhibited
TGF-β1–induced pSmad3L at Thr179 without affecting the
phosphorylation of the remaining linker region sites (Figure 6, A
and B). To assess the role of Smad3 phosphorylation at Thr179
in TGF-β1–induced EMT and migration of A549 cells, we
used recombinant lentivirus constitutively expressing Smad3T179V
mutant, in which Thr179 phosphorylation site is replaced
with Val. Western blotting (Figure 6C ) and immunofluorescence
staining (Figure 6D) of E-cadherin showed that TGF-β1–induced
repression of E-cadherin was significantly abolished in cells infected
with lentivirus carrying Smad3T179V gene compared with cells
infected with empty vector lentivirus. Consistent with this result,
TGF-β1–mediated suppression of E-cadherin promoter activity
was markedly rescued by co-transfection with Smad3T179V, but not
with Smad3WT, plasmid DNA (Figure 6E ). In line with these
results, ChIP assay revealed that TGF-β1–induced enrichment of
Smad3 on the -616/-623 region of Snail promoter was completely
abolished in cells infected with lentivirus carrying Smad3T179V
Figure 5. Expression of Smad3 linker mutant that lacks phosphorylation sites attenuates TGF-β1–induced EMT, migration, and MMP2
activation in A549 lung cancer cells. (A) Schematic representation of Smad3 wild type (S3WT) and mutant lacking phosphorylation sites in
the linker region (S3EPSM). A549 cells infected with lentivirus carrying expression vector for Myc-tagged Smad3-WT (Myc-S3WT) or
Myc-tagged Smad3-EPSM (Myc-S3EPSM), or its corresponding empty vector (pCAG) were stimulated with 5 ng/ml of TGF-β1 for 36 hours
and then subjected to Western blot analysis using anti-E-cadherin, anti-N-cadherin, anti-vimentin, and anti-Myc antibodies (B) and
immunofluorescence staining for E-cadherin and Myc-S3EPSM (C). (D) A549 cells (1 × 104) that were infected as in B were seeded on
8-mm porous Transwell chambers and then stimulated with treatment with 5 ng/ml of TGF-β1 for 36 hours. Transmigrating cells were
stained and counted as in Figure 2B. Quantitative data are shown as themean± SD of three independent experiments. **P b .01. (E) A549
cells infected with lentivirus as in B were stimulated with 5 ng/ml of TGF-β1 for 24 hours, the culture medium from indicated cells was
collected, and MMP2 activities were measured by gelatin zymography. (F) A549 cells were transiently transfected with MMP2
promoter-reporter construct and vector for Smad3-EPSM (S3EPSM) or Smad3T179V (S3T179V) or the corresponding empty vector (pcDNA)
and then stimulated with 5 ng/ml of TGF-β1 for 24 hours. All cells were then assayed for relative luciferase activity. All quantitative data are
the mean ± SD of three independent experiments. **P b .01.
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empty vector or Smad3 wild-type gene (Figure 6F ). In parallel,
TGF-β1–induced Snail promoter activity was markedly decreased
by overexpression of Smad3T179V, but not of Smad3WT, plasmid
DNA (Figure 6G ). Furthermore, lentivirus-mediated ectopic
expression of Smad3T179V in A549 cells resulted in significant
attenuation of cell migration (Figure 6H ) induced by TGF-β1.
TGF-β1–induced increases of MMP2 gene promoter activity were
also fully impaired by overexpression of Smad3T179V (Figure 6I ).
These results clearly suggest that the ablation of Smad3 phosphor-
ylation at Thr179 is responsible for the suppression by kaempferol of
TGF-β1–induced EMT, cell migration, and MMP2 activation in
A549 lung cancer cells.
Kaempferol Suppresses TGF-β1–Induced pSmad3L at Thr179
and Metastatic Responses Through Akt Inhibition
Previous study had identified PI3K as a direct target molecule for
the inhibitory effects of kaempferol on neoplastic cell transformation
[25]. It has been also reported that Akt, a downstream effector of
PI3K, plays an important role in the regulation of TGF-β signaling
through cross talk with canonical Smad pathway [33]. Theseprompted us to ask whether the ablation of PI3K-Akt pathway by
kaempferol is responsible for the inhibition of TGF-β1–induced
pSmad3L and metastatic cellular responses. Treatment of A549 cells
with TGF-β1 resulted in rapid phosphorylation of Akt, but the effect
was completely abrogated by kaempferol (Figure 7A). Pretreatment
with AktIV, a specific inhibitor of Akt, completely reversed changes in
TGF-β1–induced EMT marker expression in a concentration-
dependent manner (Figure 7B). Consistent with this result, TβRI
(T204D)-induced repression of E-cadherin promoter activity was
significantly rescued by co-transfection with dominant negative forms
of p85α or Akt (Figure 7C ). ChIP and RT-PCR also revealed that
TGF-β1–induced Smad3 binding to the Snail promoter (Figure 7D)
and Snail expression at mRNA level (Figure 7E ) were effectively
weakened by treatment with AktIV or LY294002, a specific inhibitor
of PI3K. In addition, treatment with AktIV or LY294002 resulted in
remarkable attenuation in TGF-β1–induced cell migration
(Figure 7F ), and TGF-β1–mediated increase of MMP2 gene
promoter activity was also significantly abolished by co-transfection
with dominant negative forms of p85αΔiSH2-N or Akt1K179M
(Figure 7G), indicating a crucial involvement of PI3K-Akt axis in
metastatic TGF-β signaling pathway.
Figure 6. Kaemferol specifically inhibits the phosphorylation of Smad3 at Thr179 that is required for TGF-β1–mediated induction of EMT,
cell migration, and MMP2 activation. (A) A549 cells were treated as in Figure 4B. (B) A549 cells treated as in Figure 4A except for the
TGF-β1 treatment for 10minutes. All cells then were subjected toWestern blot analysis using specific phosphopeptide antibodies against
the phosphorylated Thr179, Ser203, Ser208, and Ser213 in the Smad3 linker region. A549 cells infected with lentivirus carrying expression
vector for Myc-tagged Smad3-T179V (Myc-S3T179V) or its corresponding empty vector (pCAG) were stimulated with 5 ng/ml of TGF-β1 for
36 hours and then subjected to Western blot analysis (C) and immunofluorescence staining (D) using anti–E-cadherin antibody. β-Actin
levels were monitored as a loading control for whole extracts. DAPI (blue) was used to stain nuclei. (E) A549 cells were transiently
transfected with E-cadherin promoter-reporter construct (E-cadherin-Luc) and Smad3-WT (S3WT), Smad3-T179V (S3T179V), or the
corresponding empty vector (pcDNA) plasmid DNA and then stimulated with 5 ng/ml of TGF-β1 for 24 hours. All quantitative data are the
mean ± SD of three independent experiments. **P b .01. (F) A549 cells infected with lentivirus carrying expression vector for Myc-tagged
Smad3 wild type (S3WT), Smad3-T179V (Myc-S3T179V), or its corresponding empty vector (pCAG) were stimulated with 5 ng/ml of TGF-β1
for 24 hours and then subjected to ChIP assay using anti-Myc antibody. The purified DNA was analyzed as in Figure 3D. (G) A549 cells
were transiently co-transfected with Snail promoter-reporter (Snail-Luc) and Smad3-WT (S3WT), Smad3-T179V (S3T179V), or the
corresponding empty vector (pcDNA) plasmid DNA and then stimulated with 5 ng/ml of TGF-β1 for 24 hours. All quantitative data are the
mean± SD of three independent experiments. **P b .01. (H) A549 cells (1 × 104) that were infected as in Figure 5Bwere seeded on 8-mm
porous Transwell chambers and then stimulated with 5 ng/ml of TGF-β1 for 36 hours. Transmigrating cells were stained and counted as in
Figure 2B. Quantitative data are shown as the mean ± SD of three independent experiments. **P b .01. (I) A549 cells were transiently
transfected with MMP2 promoter-reporter construct (MMP2-Luc) and Smad3-WT (S3WT), Smad3-T179V (S3T179V), or the corresponding
empty vector (pcDNA) plasmid DNA and then stimulated with 5 ng/ml of TGF-β1 for 24 hours. All quantitative data are the mean ± SD of
three independent experiments. **P b .01.
Neoplasia Vol. 17, No. 7, 2015 Kaempferol Suppresses TGF-β1–Induced EMT Jo et al. 533We further addressed whether Akt activation is necessary for
TGF-β1–induced pSmad3L in A549 cells. Similar to the kaempferol
effect, treatment with AktIV resulted in selective inhibition of
TGF-β1–induced phosphorylation of Smad3 at Thr179 (Figure 8A).
In contrast, overexpression of constitutively active form of Akt alone
resulted in an increase of phosphorylation of Smad3 at Thr179
compared with expression of control counterpart (Figure 8B).
Treatment with TGF-β1 resulted in increase of Akt binding with
Smad3, and the binding reached a peak at 30 minutes and then
declined to baseline at 60 minutes (Figure 8C ). The TGF-β1–
induced binding of Akt with Smad3 was completely abolished bypretreatment with kaempferol (Figure 8C ). Given these findings that
Akt controls phosphorylation of Smad3 at Thr179, we next assessed
whether Akt-mediated phosphorylation of Smad3 at Thr179 would
be sufficient to drive TGF-β1–induced repression of E-cadherin.
Reporter gene assay revealed that TGF-β1–induced repression of
E-cadherin promoter activity was further augmented in cells
transfected with constitutively active forms of p110αK227E or
Akt1E40K compared with that in cells transfected with empty vector.
In contrast, in cells co-transfected with Smad3T179V and p110αK227E
or Akt1E40K, TβRIT204D-induced repression of E-cadherin promoter
activity was significantly rescued compared with that in cells
Figure 7. PI3K/Akt1 pathway is crucial for TGF-β1–induced EMT, cell migration, and MMP2 activation and is inhibited by KF. (A) A549 cells
were treated as in Figure 4A except for the TGF-β1 treatment for 90 minutes. (B) A549 cells were pretreated with DMSO or AktIV at the
indicated concentrations for 30minutes and then stimulated with 5 ng/ml of TGF-β1 for 48 hours. All cells were then subjected toWestern
blot analysis using anti–phospho-Akt, anti–E-cadherin, and anti–N-cadherin antibodies. β-Actin levels were monitored as a loading control
for whole extracts. (C) A549 cells were transiently transfected with E-cadherin promoter-reporter (E-cadherin-Luc) combination with
constitutively active TβRI (CA-TβRI, TβRI-T204D)-, dominant negative p85 (DN-p85, p85ΔiSH2-N)-, and dominant negative Akt1 (DN-Akt1,
Akt1-K179M)-expressing plasmids and the corresponding empty vector (pcDNA). All quantitative data are the mean ± SD of three
independent experiments. **P b .01. (D) A549 cells were pretreated with DMSO, 10 μM of LY294002, or 2.5 μM of AktIV for 30 minutes
before treatment with 5 ng/ml of TGF-β1 for 24 hours and then subjected to ChIP assay using anti-Smad3 antibody. The purified DNA was
analyzed as in Figure 3D. (E) A549 were pretreated with DMSO or 2.5 μMof AktIV for 30 minutes before treatment with 5 ng/ml of TGF-β1
for 3 hours, after which the expression of Snail mRNA was determined by RT-PCR analysis. β-Actin levels were monitored as a loading
control for total RNA. (F) A549 cells (1 × 104) seeded on 8-mm porous Transwell chambers were treated as in D. Transmigrating cells were
stained and counted as in Figure 2B. Quantitative data are shown as the mean ± SD of three independent experiments. **P b .01.
(G) A549 cells were co-transfected as in C except for transfection with MMP2-Luc instead of E-cadherin-Luc and then stimulated with
5 ng/ml of TGF-β1 for 24 hours. All quantitative data are the mean ± SD of three independent experiments. **P b .01.
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Akt1 as a key mediator in TGF-β signaling pathway leading to
E-cadherin repression through inducing the phosphorylation of
Smad3 at Thr179.
Discussion
Although kaempferol has been extensively studied as a natural
flavonoid that possesses chemopreventive effect on cancer, its
antimetastatic effect has been less addressed. The enhancement of
EMT in cancer cells is known to increase the risk of metastasis and
closely associated with poor prognosis of many types of cancer.
Fibroblast growth factor (FGF) signaling is important in promotion
of EMT and invasion of cancer cells [34]. Kaempferol inhibits
tyrosine phosphorylation of FGF receptor by FGF stimulation [35].
The study by Huang et al suggested that estrogen-related receptor
(ERR) α promotes the migration and invasion of lung cancer A549cells by inducing EMT [36]. Kaempferol was reported to inhibit
cancer cell growth by antagonizing ERRα and ERRγ activities [37].
These findings strongly suggest that kaempferol may exert its
antimetastatic activity through targeting key components of several
signaling pathways involved in tumor metastasis. TGF-β1 potently
induces EMT in epithelial tumor cells, conferring them migratory
and invasive properties. Our data showed that kaempferol strongly
inhibited TGF-β1–induced EMT, migration, and MMP-2 activation
in human A549 lung cancer cells, which strongly support its potential
as an antitumor agent that suppresses tumor metastasis.
Smad2 and Smad3 are key mediators for TGF-β signaling in both
normal and pathological conditions. It has been established that
Smad2 and Smad3 have distinct functions in TGF-β1–induced
cellular responses. For example, Smad3 is critical to inducing
TGF-β1–mediated growth inhibition [38,39], whereas Smad2 is
uniquely essential for TGF-β signaling in CD4 T cell differentiation
Figure 8. Akt1 directly phosphorylates Smad3 at Thr179, and it mediates TGF-β1–induced E-cadherin repression. (A) A549 cells were
pretreated with DMSO or AktIV at the indicated concentrations for 30 minutes and then stimulated with 5 ng/ml of TGF-β1 for 30 minutes.
(B) A549 cells were transfected with vector for constitutively active HA-Akt1 (HA-CA-Akt1, HA-Akt1-E40K) or its corresponding empty
vector, pcDNA, for 24 hours. All cells were then subjected to Western blot analysis using antibodies against phospho-Smad3 (Thr179),
phospho-Smad3 (Ser208), phospho-Smad3 (Ser423/425), and HA. (C) A549 cells were pretreated with DMSO or 25 μM of KF for 30
minutes before treatment with 5 ng/ml of TGF-β1 for the indicated periods, and cell lysates were immunoprecipitated with anti-Smad3
antibody and immunoblotted as indicated. β-Actin levels were monitored as a loading control for whole extracts. (D) A549 cells were
cotransfected with E-cadherin promoter-reporter construct (E-cadherin-Luc) in combination with constitutively active TβRI (CA-TβRI,
TβRI-T204D)-, constitutively active p110α (CA-p110α, p110α-K227E)-, constitutively active Akt1 (CA-Akt1, Akt1-E40K)-, and Smad3-T179V
(S3T179V)-expressing plasmids and the corresponding empty plasmid (pcDNA). All quantitative data are the mean ± SD of three
independent experiments. **P b .01; ***P b .005.
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was required for TGF-β1–induced E-cadherin repression and
up-regulation of snail gene expression in A549 lung cancer cells. It
was also notable that kaempferol significantly inhibited Smad3
binding to the promoter of snail gene and the induction of snail
expression upon TGF-β1 stimulation, whereas it did not affect the
canonical activation of Smad3 (C-terminal phosphorylation, complex
formation with Smad4, and translocation into the nucleus) induced
by TGF-β1. These results imply the possibility that Smad3 activity
can be inhibited noncanonically by kaempferol before or after it
enters the nucleus in response to TGF-β1.
Smad3 can be regulated noncanonically through phosphorylation
of its linker region. The recent discovery of C-terminal domain
phosphatase 1 as a specific phosphatase for Smad3 dephosphorylation
in the linker region [41,42] highlights the need to consider
Smad-linker phosphorylation as a reversible and tightly controlled
TGF-β signaling event. Actually, the study by Matsuura et al.
demonstrated that phosphorylation of Smad3 linker region by
cyclin-dependent kinase inhibits its antiproliferative function, thus
facilitating cell cycle progression [43]. Furthermore, increased
phosphorylation of Smad3 linker region has been identified in
many types of cancer cells and was proven to contribute to the
TGF-β1–mediated signaling events to facilitate protumorigenicoutcomes [44,45]. In line with these observations, our data
demonstrated that TGF-β1 induced Smad3 linker phosphorylation,
and Smad3 mutant lacking linker phosphorylation sites could reverse
metastatic responses to TGF-β1 in A549 lung cancer cells. A
remarkable finding is that the inhibitory effect of kaempferol on
increased Smad3 linker phosphorylation by TGF-β1 treatment was
specifically limited to Thr179 residue, but not to other linker sites,
and it was sufficient to reverse TGF-β1–induced EMT and migration
in A549 cells by expression of Smad3T179V alone. TGF-β1–induced
Smad3 binding to the Snail promoter and subsequent repression of
E-cadherin were also dependent on Smad3 phosphorylation at
Thr-179. However, TGF-β1–induced p21WAF1 expression and cell
cycle arrest in A549 cells were not affected by kaempferol treatment
and overexpression of Smad3T179V (Supplementary Figure S1, A and
B). These results newly characterized an important role of the Thr179
phosphorylated form of Smad3 in the metastatic TGF-β signaling in
A549 lung cancer cells. However, we do not exclude the possibility
that other Smad3 linker sites for phosphorylation could contribute to
TGF-β1–induced metastatic responses.
A growing body of evidence has shown that the linker domain of
Smad3 undergoes regulatory phosphorylation by various intracellular
signaling kinases, including mitogen-activated protein kinase,
cyclin-dependent kinase, glycogen synthase kinase 3-β, and protein
Figure 9. A model illustrating the mechanism underlying inhibition
of TGF-β1–induced EMT and cell migration by KF. In A549 lung
cancer cells, TGF-β1 activates both canonical Smad pathway and
noncanonical PI3K-Akt1 pathway. The activated Akt1 directly
interacts with Smad3 and phosphorylated it at Thr179 in the linker
region, which leads to induction of Snail, N-cadherin, and MMP2
expression as well as repression of E-cadherin that are necessary
for induction of EMT and migration of cancer cells. Kaempferol
inhibits TGF-β1–induced EMT and cell migration by suppressing its
downstream Akt1 activity through binding with PI3K.
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previous study by Nguyen et al. showed that kaempferol activated
ERK1/2 in A549 lung cancer cells [47], we investigated the
involvement of ERK1/2 in phosphorylation of Smad3 linker region
and EMT induced by TGF-β1. Pretreatment of A549 cells with
U0126, a specific inhibitor of MEK1/2, completely inhibited
phosphorylation of ERK1/2 but had no effects on phosphorylation
of Smad3 linker region and EMT upon TGF-β1 stimulation
(Supplementary Figure S2, A and B), indicating that ERK1/2 is not
associated with these TGF-β1 responses in A549 cells. The PI3K/Akt
pathway plays an important role in tumor development [48].
Recently, Lee et al. demonstrated that PI3K is a direct target
molecule for the inhibitory effects of kaempferol on neoplastic cell
transformation [25]. Our data demonstrated that TGF-β1–induced
EMT and cell migration were dependent on the activation of the
PI3K/Akt axis. Consistent with the effect of kaempferol on TGF-β1–
induced Smad3 linker phosphorylation, Akt activation or inhibition
showed prominent effects on Smad3 phosphorylation at Thr179
only. Moreover, Akt interacted with Smad3 in the presence of
TGF-β1. These observations suggest the direct link between PI3-K/
Akt axis and Smad3 linker phosphorylation at Thr179 in metastatic
TGF-β signaling, thus extending our knowledge about the molecular
mechanism of EMT and cell migration induced by TGF-β1 in
cancer cells.
In summary, this study provides the first evidence showing that the
natural compound kaempferol can inhibit the TGF-β1–inducedEMT and cell migration in human lung cancer cell by targeting
phosphorylation of Smad3 linker region. The presenting data also
highlight a loss of PI3K/Akt-mediated Smad3 phosphorylation at
Thr179 as a key mechanism of inhibition by kaempferol of oncogenic
TGF-β1 signaling (Figure 9) and suggest that the pharmacologic
inhibition of Smad3 phosphorylation at Thr179 can be an effective
strategy to impede lung cancer progression.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.neo.2015.06.004.
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